Results 161 to 170 of about 66,261 (304)

Dipeptidyl Peptidase-4 Inhibitor

Journal of the American College of Cardiology, 2012
openaire   +1 more source

Dipeptidyl peptidase-4 inhibitors and osteoporosis

Journal of the Chinese Medical Association, 2022
Wen-Ling Lee, Fa-Kung Lee, Peng-Hui Wang
openaire   +1 more source

Repurposing dipeptidyl peptidase-4 inhibitor for Parkinson's disease prevention: A drug-target Mendelian randomization study. [PDF]

Neurotherapeutics
Lee JY, Park DG, Sung J.
europepmc   +1 more source

Sustained glucagon-like peptide-1 receptor agonist treatment improves glycemic control and reduces all-cause mortality compared to dipeptidyl peptidase-4 inhibitors: A real-world target trial emulation in type 2 diabetes. [PDF]

Diabetes Obes Metab
Abstract Background Glucagon‐like peptide 1 receptor agonists (GLP‐1 RAs) improve glycemic outcomes in people with type 2 diabetes, but their generalizability to routine clinical practice remains uncertain. Aim To evaluate the real‐world effectiveness of sustained GLP‐1 RA use on haemoglobin A1c (HbA1c) over 1 to 4.5 years, using dipeptidyl peptidase 4
Sørensen KK, Yazdanfard PDW, Zareini B, Wood-Kurland HK, Pedersen-Bjergaard U, Andersen MP, Michelsen J, Imberg H, Lind M, Hallström S, Lanzinger S, Munch A, Ohlendorff JS, Gerds TA, Torp-Pedersen C, REDDIE Consortium.   +15 more
europepmc   +2 more sources

Dipeptidyl peptidase-4 (DPP-4; CD26) [PDF]

Science-Business eXchange, 2014
openaire   +1 more source

Sodium–glucose cotransporter 2 inhibitors for hypertension in cardiovascular–kidney–metabolic syndrome

Experimental Physiology, EarlyView.
Abstract The antihypertensive mechanism of sodium–glucose cotransporter 2 (SGLT2) inhibitors has been traditionally attributed to osmotic diuresis. However, emerging evidence reveals multifaceted mechanisms beyond diuresis, including regulation of the renin–angiotensin–aldosterone system, sympathetic nervous system suppression, ion homeostasis ...
Chunxiang Xu, Xingyu Qiu, Nan Xu, Gensheng Zhang, Enyin Lai, Liang Zhao   +5 more
wiley   +1 more source

ERRATUM: Effects of dipeptidyl peptidase-4 inhibitor in insulin-resistant rats with myocardial infarction. [PDF]

J Endocrinol
Apaijai N, Inthachai T, Lekawanvijit S, Chattipakorn SC, Chattipakorn N.   +4 more
europepmc   +1 more source

Pancreatic Islet Cell Crosstalk: Insight Into α‐/β‐Cell Compensatory Mechanisms

Comprehensive Physiology, Volume 16, Issue 3, June 2026.
α‐cell remodeling compensates for impaired β‐cell function. Intra‐islet glucagon/GLP‐1 signaling is upregulated and becomes essential in prediabetic islets. Flexible receptor engagement reflects functional plasticity in hormonal control of insulin secretion. Created in BioRender. Plecita, L. (2026); https://BioRender.com/pgjjg3m.
Štěpánka Benáková, Blanka Holendová, Jurij Dolenšek, Monika Křivonosková, Andraž Stožer, Lydie Plecitá‐Hlavatá   +5 more
wiley   +1 more source

Health economic evaluation of dipeptidyl peptidase-4 inhibitors

Indian Journal of Endocrinology and Metabolism, 2011
Vishvas Garg
doaj   +1 more source

Dipeptidyl Peptidase 4 Inhibitors: Novel Therapeutic Agents in the Management of Type II Diabetes Mellitus. [PDF]

Pharmacoepidemiol Drug Saf
Aloke C, Adelusi OA, Onisuru OO, Iwuchukwu EA, Achilonu I.   +4 more
europepmc   +1 more source